Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Top Page
Raily Aesthetic Medicine International Holdings Limited
(2135)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$0.15
▼(-10.59% Downside)
Action:ReiteratedDate:12/20/25
The overall stock score is primarily impacted by the company's weak financial performance, characterized by persistent losses and increasing leverage. While technical analysis shows a positive short-term trend, the overbought RSI suggests caution. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further weighing down the score.
Positive Factors
Secular market growth in aesthetic medicine
Raily sits in a structurally expanding market for non- and minimally invasive aesthetic treatments. Long-term demographic and consumer-preference trends favor less-invasive procedures, enlarging the addressable market and supporting sustained demand for clinics, services, and repeat clients.
Negative Factors
Persistent net losses and margin pressure
Sustained negative margins and recurring losses signal structural profitability issues. Continued negative EBIT/EBITDA limits reinvestment capacity, undermines shareholder returns, and raises the bar for necessary revenue or efficiency improvements to reach sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Secular market growth in aesthetic medicine
Raily sits in a structurally expanding market for non- and minimally invasive aesthetic treatments. Long-term demographic and consumer-preference trends favor less-invasive procedures, enlarging the addressable market and supporting sustained demand for clinics, services, and repeat clients.
Read all positive factors
Raily Aesthetic Medicine International Holdings Limited (2135) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$84.68M
Dividend YieldN/A
Average Volume (3M)289.64K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue Growth-20.66%
EPS Growth-77.84%
CountryHK
Employees290
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.02
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.05
P/FCF Ratio-0.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Raily Aesthetic Medicine International Holdings Limited Business Overview & Revenue Model
Company Description
Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services. The company operates through three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipm...
How the Company Makes Money
Raily Aesthetic Medicine generates revenue primarily through its diverse offerings of aesthetic treatments and services. The company's revenue model is centered around fee-for-service income from patients seeking cosmetic procedures, which can inc...
Raily Aesthetic Medicine International Holdings Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 166.47M | 199.34M | 189.38M | 164.52M | 188.37M | 164.54M |
| Gross Profit | 52.08M | 71.41M | 71.49M | 66.78M | 69.69M | 80.17M |
| EBITDA | -14.90M | -34.29M | -6.03M | 3.89M | -6.00M | 17.48M |
| Net Income | -65.17M | -59.21M | -32.46M | -15.91M | -17.69M | 4.25M |
Balance Sheet | ||||||
| Total Assets | 240.89M | 249.92M | 273.60M | 302.65M | 344.73M | 272.33M |
| Cash, Cash Equivalents and Short-Term Investments | 35.73M | 28.87M | 39.79M | 78.78M | 121.72M | 148.40M |
| Total Debt | 72.96M | 56.37M | 51.78M | 48.22M | 67.45M | 32.19M |
| Total Liabilities | 152.57M | 154.41M | 141.01M | 136.77M | 162.37M | 85.58M |
| Stockholders Equity | 97.97M | 104.13M | 138.12M | 166.08M | 178.22M | 185.87M |
Cash Flow | ||||||
| Free Cash Flow | 4.53M | -38.59M | -10.00M | -21.13M | -18.25M | 5.56M |
| Operating Cash Flow | 10.29M | 6.01M | 8.02M | -2.27M | -2.47M | 14.16M |
| Investing Cash Flow | -10.61M | -12.70M | -26.14M | 558.00K | -82.45M | -13.34M |
| Financing Cash Flow | 1.51M | 19.43M | -10.48M | -25.65M | 11.97M | 92.67M |
Raily Aesthetic Medicine International Holdings Limited Technical Analysis
Positive
0.17
Price Trends
0.15
Negative
0.15
Positive
0.13
Positive
Market Momentum
<0.01
Negative
52.19
Neutral
79.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2135, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.13, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.19 is Neutral, neither overbought nor oversold. The STOCH value of 79.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2135.
Raily Aesthetic Medicine International Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$4.89B | 18.12 | 33.08% | 1.97% | 28.53% | 22.34% | |
58 Neutral | HK$56.73M | 362.73 | -19.93% | ― | -2.91% | 55.41% | |
53 Neutral | HK$22.46M | -197.60 | 138.68% | ― | -20.81% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$84.68M | -2.11 | -64.49% | ― | -20.66% | -77.84% | |
43 Neutral | HK$84.86M | -4.87 | -27.01% | ― | -11.68% | -71.01% | |
41 Neutral | HK$16.65M | -2.29 | 26.12% | ― | 14.64% | -81.95% |
* Healthcare Sector Average
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.15
0.04
31.03%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
19.50
3.56
22.33%
HK:8161
MediNet Group Ltd.
0.54
0.20
58.82%
HK:8307
Medicskin Holdings Ltd.
0.14
>-0.01
-4.67%
HK:8357
Republic Healthcare Limited
0.14
0.07
91.55%
HK:8437
RMH Holdings Limited
0.25
0.08
47.06%
Raily Aesthetic Medicine International Holdings Limited Corporate Events
Raily Aesthetic Medicine to Consolidate New Subsidiary After HK$3.5 Million Share Subscription
Jan 6, 2026
Raily Aesthetic Medicine International Holdings Limited has announced that its subsidiary Miusee Beauty and a target company have entered into a subscription agreement with two external investors, under which 233,335 new shares of the target compa...
Raily Aesthetic Medicine Redirects Remaining IPO Proceeds to Working Capital Amid Weak Shanghai Market
Jan 2, 2026
Raily Aesthetic Medicine International Holdings has reallocated approximately HK$8.4 million of unutilised IPO net proceeds, originally earmarked for organic expansion of its aesthetic medical institutions network, to general working capital, with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.